Back to top
more

Elevance Health, Inc. (ELV)

(Real Time Quote from BATS)

$500.00 USD

500.00
2,142,054

-5.16 (-1.02%)

Updated Oct 3, 2024 09:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Chemed (CHE) Q3 Earnings Surpass Estimates, EPS View Up

by Zacks Equity Research

Chemed's (CHE) full-year VITAS revenues, prior to Medicare Cap, are once again estimated to decline.

Inari Medical (NARI) Q3 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Inari Medical's (NARI) third-quarter results benefit from significant progress made across all its growth drivers.

Inogen (INGN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Inogen's (INGN) third-quarter results benefit from higher revenues in its domestic business-to-business sales channel.

Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View

by Zacks Equity Research

Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.

Nevro (NVRO) Q3 Earnings Beat Estimates, 2022 View Revised

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improved on a year-over-year basis in Q3, partly owing to robust domestic performance.

QuidelOrtho (QDEL) Q3 Earnings Top Estimates, 2022 View Revised

by Zacks Equity Research

QuidelOrtho's (QDEL) robust results in POC and Donor Screening product lines drives its third-quarter 2022 top line.

Charles River (CRL) Q3 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Headwinds associated with foreign exchange due to the strengthening of the U.S. dollar and interest expense due to a rising interest rate environment increase concerns for Charles River (CRL).

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.

CVS Health (CVS) Q3 Earnings Surpass Estimates, View Up

by Zacks Equity Research

Robust sales growth across all three operating segments drive CVS Health's (CVS) top line.

Hologic (HOLX) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Lower sales of COVID-19 assays and supply chain challenges drag Hologic's (HOLX) top line down.

Fresenius Medical's (FMS) Q3 Earnings and Revenues Top

by Zacks Equity Research

Fresenius Medical's (FMS) third-quarter revenues benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.

McKesson (MCK) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

McKesson's (MCK) fiscal second-quarter 2023 results benefit from segmental growth.

Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut

by Zacks Equity Research

Catalent (CTLT) records robust first-quarter fiscal 2023 results of its Pharma and Consumer Health segment despite overall soft performance.

IDEXX (IDXX) Q3 Earnings Beat Estimates, 2022 EPS View Down

by Zacks Equity Research

IDEXX's (IDXX) Q3 top-line performance rides on strong CAG Diagnostics recurring revenue growth.

Stryker's (SYK) Q3 Earnings Miss Estimates, Volume Improves

by Zacks Equity Research

Stryker's (SYK) third-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.

Ecolab (ECL) Q3 Earnings & Revenues Miss Mark, Margins Down

by Zacks Equity Research

Ecolab's (ECL) robust performance across all its segments drives its Q3 sales, despite business challenges.

Henry Schein (HSIC) Q3 Earnings In Line, 2022 Sales View Down

by Zacks Equity Research

Severe currency headwinds and lower sales of PPE and COVID-19 test kits affect Henry Schein's (HSIC) top line in Q3.

Teleflex (TFX) Q3 Earnings Top Estimates, Adjusted EPS View Cut

by Zacks Equity Research

For UroLift, Teleflex (TFX) currently assumes 2022 revenues to be roughly $320 million, down from the prior guidance of $335 million.

Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

ResMed (RMD) Q1 Earnings In Line, Operating Margin Falls

by Zacks Equity Research

ResMed (RMD) continues to increase its access to semiconductor communications chips.

Amedisys (AMED) Q3 Earnings Miss Estimates, Guidance Cut

by Zacks Equity Research

Within Amedisys (AMED) Home Health and Hospice, the reinstatement of sequestration reduces growth in Q3.

Avantor (AVTR) Q3 Earnings Top Estimates, 2022 EPS View Cut

by Zacks Equity Research

Avantor's (AVTR) robust performance across the majority of its segments drives its Q3 sales, despite business challenges.

Edwards Lifesciences (EW) Q3 Earnings Miss, Margins Rise

by Zacks Equity Research

Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.

DexCom (DXCM) Q3 Earnings Beat Estimates, Guidance Revised

by Zacks Equity Research

DexCom's (DXCM) third-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.